Lipids & metabolic liver disease
Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes
Authors' conclusion
Both short and long sleep duration are associated with an increased risk of MASLD, cirrhosis, HCC, and liver-related mortality. Maintaining a moderate sleep duration of 7 to 8 hours per day could be crucial to prevent against this escalating public health concern.
Study context
- Population
- Middle-aged and older adults from the UK Biobank without prior liver diseases
- Participants
- 489,261 participants
- Exposure
- Self-reported daily sleep duration categories vs 7 h
- Outcome
- MASLD
- Follow-up
- Median (IQR) 13.8 (1.5) years
Methodological detailspopulation-based, UK Biobank, Sleep duration self-reported at baseline survey, Outcomes ascertained through linked hospital records and death registries
- Population-based
- UK Biobank
- Sleep duration self-reported at baseline survey
- Outcomes ascertained through linked hospital records and death registries
Main finding
As reported in the abstract
MASLD (7,133 cases)
Each group vs 7 hoursHazard ratio (95% CI)
≤ 5 hours
1.44(1.32–1.57)
6 hours
1.17(1.09–1.24)
8 hours
1.05(0.99–1.11)
≥ 9 hours
1.35(1.24–1.46)
Observational data: associations, not effects.
Secondary outcomes
Cirrhosis (5,527 cases), hepatocellular carcinoma (HCC) (1,126 cases), liver-related mortality (1,125 cases)
- Similar trends observed for cirrhosis, HCC and liver-related mortality
MASLD by subgroup (BMI, hypertension, insomnia)
- U-shaped association more pronounced among participants without abnormal BMI (overweight and obese), hypertension or insomnia
- P for interaction < 0.05
Original publication
Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes. Diabetes Metab. Published 19 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →